Blair William & Co. IL Reduces Position in Illumina, Inc. (NASDAQ:ILMN)

Blair William & Co. IL trimmed its holdings in Illumina, Inc. (NASDAQ:ILMN) by 7.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 22,332 shares of the life sciences company’s stock after selling 1,845 shares during the period. Blair William & Co. IL’s holdings in Illumina were worth $2,984,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Versant Capital Management Inc raised its holdings in Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 146 shares during the last quarter. Golden State Wealth Management LLC purchased a new stake in shares of Illumina in the fourth quarter valued at approximately $32,000. Assetmark Inc. increased its holdings in shares of Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after purchasing an additional 296 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new position in Illumina during the fourth quarter worth approximately $45,000. Finally, Lee Danner & Bass Inc. acquired a new position in Illumina during the fourth quarter worth $48,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Robert W. Baird cut their target price on Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a research note on Wednesday, March 5th. Morgan Stanley cut their price objective on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 11th. Piper Sandler boosted their target price on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, February 10th. TD Cowen downgraded shares of Illumina from a “buy” rating to a “hold” rating and cut their price target for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Finally, Citigroup decreased their price objective on Illumina from $130.00 to $90.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Illumina presently has a consensus rating of “Moderate Buy” and a consensus price target of $140.90.

Illumina Price Performance

Illumina stock opened at $79.34 on Tuesday. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 52-week low of $77.54 and a 52-week high of $156.66. The firm has a market cap of $12.57 billion, a PE ratio of -10.33, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The company’s 50 day moving average is $101.65 and its two-hundred day moving average is $126.49.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, research analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.